Phase II of Erlotinib an Epidermal Growth Factor Receptor Inhibitor in the Treatment of Myelodysplastic Syndrome
MDS is a neoplastic clonal stem disorder characterized by bone marrow failure with
cytopenia, dyslastic morphological features and tendency to progress to acute myeloid
leukemia. It is estimated that MDS is the most common hematological malignancy in the USA.
Several treatment options are available for MDS ranging from supportive care, growth factor
use, chemotherapy, stem cell transplantation, and newer novel agents such as thalidomide,
lenalidomide, and hypomethylating agents. Each of the different available treatments for
MDS work in certain subset and relatively small percentage of patients, keeping the door
open for novel therapeutic strategies to be explored. The NIH has published requests for
applications on myeloproliferative and myelopdysplastic syndrome emphasizing the need for
more research in this area.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
First 20 patients will be evaluated for overall response rate (CR, PR or HI).
Estimated to be about 1 year.
Carl W Siegrist, M.D.
University of Cincinnati
United States: Institutional Review Board
|University of Cincinnati||Cincinnati, Ohio 45267-0502|